Jonathan

Himmelfarb

MD

National and International Responsibilities

Editorial Board, Clinical Journal of the American Society of Nephrology
2018-present

Standing member, NIDDK DDK-D Study Section
2018

Member, Hemodialysis Novel Therapies Steering Committee
2018

Member, Hemodialysis Novel Therapies Safety Committee
2018

Member, ASSESS Biomarker Partners Committee
2018

President, American Society of Nephrology
2014 - 2015 

Member, Life Center NW Governing Board
2013-2017

Fellow, Royal College of Physicians
2013

International Society of Nephrology
2012

National Kidney Foundation
2012

Renal Physician’s Association
2012

Councilor, American Society of Nephrology
2009 - 2016

Fellow, American Society of Nephrology
2009

Honors

Donald W. Seldin Award, National Kidney Foundation
2017

Best Doctors in America
2012-2013

US News & World Report, Top Doctors
2012-2013

Elected Fellow of the Royal College of Physicians
2012

National Kidney Foundation J. Michael Lazarus Award for Excellence in Dialysis Research
2012

National Registry of Who’s Who
2011

Who’s Who in America, Science, and Engineering
2011

Paul Teschan Lectureship, Vanderbilt University Medical School
2011

John Harrington Lectureship, School of Medicine, Tufts University
2011

Best Doctors in America
2009-2010

Department of Medicine Award for Teaching Excellence
1998

Department of Medicine Award for Teaching Excellence
1991

Education & Training

Nephrology Fellowship
Maine Medical Center
Portland, ME
1988

Nephrology Fellowship 
Brigham and Women's Hospital
Boston, MA
1986-1988

Medicine Residency
Maine Medical Center
Portland, ME
1984-1986

Medical Internship
Maine Medical Center
Portland, ME
1983-1984

Medical School
George Washington University
Washington, DC
1979-1983

Clinical Interests

• Clinical and translational kidney research

Research Interests

• Epidemiology of acute kidney injury and chronic kidney disease, with a focus on public health
• Metabolic complications associated with kidney disease, including oxidative stress, inflammation, and insulin-resistant uremic toxicity
• Altered drug metabolism, and mechanisms of drug-induced nephrotoxicity in kidney disease.
• Biomarker discovery and evaluation in kidney disease
• Clinical trials in ESRD, CKD, and AKI

Publications

Links